INVESTORS

AT A GLANCE

"A pioneer of digital therapeutics, Voluntis was the first such company to go public. Personally, and in the name of the entire Voluntis team, I would like to thank all of our new and historic shareholders for their faith in us. This investment of €30.1M will allow us to continue our commitment to patients and healthcare professionals, helping them better manage treatment in the hopes that this improves real-world efficacy." - Pierre Leurent, CEO of Voluntis

STOCK INFORMATION

EURONEXT Paris

WHAT'S NEW

Upcoming events

27 Mar. 2020

Publication of 2019 results

CONFERENCE CALL

20 May 2020

Annual General Assembly

SURESNES

29 Sept. 2020

Publication of H1 2020 results

CONFERENCE CALL

H1 2019 Financial Results

NEWS

Voluntis Announces New Pharma Collaboration in Oncology

PRESS RELEASES

DOCUMENTS

Sorry, but ther are no document, please choose other criterias

CONTACT THE INVESTOR RELATIONS TEAM

NewCap
Louis-Victor Delouvrier
21, place de la Madeleine
75008 Paris, France
Tel: +33 (0)1 44 71 94 94
Email: voluntis@newcap.eu